Richard J. Ablin

Corporate Officer/Principal at Tetragenex Pharmaceuticals, Inc.

Consumer Services

Health Technology

Profile

Richard J.
Ablin is currently the Director of Tetracycline Evaluation at Tetragenex Pharmaceuticals, Inc. He was previously the Director and Research Associate Professor at The State University of New York from 1983 to 1989.
Ablin received his doctorate degree from the State University of New York at Buffalo in 1967.

Richard J. Ablin active positions

Companies	Position	Start
Tetragenex Pharmaceuticals, Inc. Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY.	Corporate Officer/Principal	2010-02-04

All active positions of Richard J. Ablin

Former positions of Richard J. Ablin

Companies	Position	End
The State University of New York	Director/Board Member	1988-12-31

See the detail of Richard J. Ablin's experience

Training of Richard J. Ablin

State University of New York at Buffalo

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Richard J. Ablin's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Tetragenex Pharmaceuticals, Inc. Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY.	Health Technology